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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The effect of rituximab on B cell and immunoglobulin production after
therapeutic apheresis has not been studied in ABO-incompatible renal transplant patients.
Methods: Twenty consecutive ABO-incompatible renal transplant patients receiving rituximab
induction and double filtration plasmapheresis were enrolled; one case was excluded because
of repeated plasmapheresis and immunoglobulin therapy (Incompatible group). The B cell
count of the Incompatible group was compared to another group of 18 ABO-compatible renal
transplant patients who were operated on during the same period (Compatible group). In the
Incompatible group, the total IgM, IgG, and IgG1-4 subclasses after transplantation were com-
pared to those before desensitization. Tacrolimus, mycophenolate mofetil, and steroids were
used for both groups.
Results: The B cell count of the Incompatible group was significantly lower than the Compa-
tible group post-transplant from Month 1 to Month 11 only. The B cell count of the Compa-
tible group also decreased for the first 6 months, suggesting that maintenance
immunosuppressive agents suppress B cells. Total IgG and IgM levels after transplantation
were significantly lower than before desensitization during the 24-month follow-up period.
The post-transplant IgG3 level was significantly lower than before desensitization for only
3 months.ave no conflicts of interest relevant to this article.
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354 M.-K. Tsai et al.Conclusion: With the aid of tacrolimus and mycophenolate mofetil, rituximab resulted in sus-
tained suppression of B cell count and total IgG and IgM. Among the IgG subclasses, IgG3 was
less sensitive to rituximab.
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ABO-incompatible (ABOi) renal transplantations were pre-
viously considered to be at high risk of rejection and
transplant failure regardless of whether splenectomy was
performed to hamper the immune response.1,2 Removal of
anti-A/B antibodies (ABab) by therapeutic apheresis has
been reported to rescue ABOi renal transplant rejection.3
With the advent of rituximab, a monoclonal anti-CD20
antibody that depletes human B cells, ABOi renal trans-
plantations have been performed in many transplant cen-
ters with very high success rates.4e6 Rituximab depletes B
cells not only in the peripheral blood but also in the lymph
nodes and transplanted kidneys.7 ABOi renal transplant
operations are currently conducted using rituximab and
various techniques of therapeutic apheresis to remove
ABab. Removal or inhibition of ABab can be temporarily
achieved by either plasmapheresis or immunoadsorption
with or without intravenous immunoglobulin.4e6 Rebound
antibody production after cessation of therapeutic aphe-
resis has been reported in patients with autoimmune dis-
eases as well as in those receiving immunoadsorption for
ABOi renal transplantation.8,9 In addition, the use of rit-
uximab after kidney transplantation has been associated
with a high risk of infectious diseases and infection-related
deaths.10 However, the effects of rituximab on B cell and
immunoglobulin production after therapeutic apheresis
have not previously been studied in ABOi renal transplant
patients.
To demonstrate the effects of rituximab on B cell and
immunoglobulin production, we retrospectively reviewed
the medical records of patients who had undergone ABOi
renal transplantation with a preconditioning regimen
including rituximab and double filtration plasmapheresis
only. The immunoglobulin levels after transplantation were
compared to those before desensitization, and the number
of B cells of the ABOi recipients was compared to a group of
ABO-compatible renal transplant patients during the same
time period.Patients and methods
Study population and design
Patients who underwent primary ABO-incompatible renal
transplantation (Incompatible group) performed in a single
hospital between January 2006 and December 2010 were
retrospectively reviewed to assess the effects of rituximab
on B cell and immunoglobulin productions. An immuno-
suppressive regimen including rituximab induction, double
filtration plasmapheresis (DFPP) and tacrolimus-based
immunosuppressive therapy was employed to bring theABO antibody titers down before live donor renal trans-
plantations were performed. The numbers of B cells of the
ABOi recipients were compared to a group of ABO-
compatible renal transplant patients who were operated
on without pretransplant rituximab and DFPP during the
same time period (Compatible group). Patients with a
positive crossmatch before transplantation were not
included, and those who received intravenous immunoglo-
bulin, rituximab or DFPP after transplantation because of
antibody-mediated rejection were also excluded. The
follow-up period was at least 12 months for all the patients.
Desensitization protocol
For ABOi renal transplantations, two doses of rituximab,
which could deplete B lymphocytes but not plasma cells,
were given before graft reperfusion: one dose of 200 mg
about 14 days before transplantation and the other during
the transplant operation. At least four sessions of DFPP
were given in order to reduce the donor-specific ABab titers
to 1:2. ABab titers were determined using the saline
method.11 Briefly, two-fold serial dilutions of sera were
made in saline and tested for agglutinating activity toward
type A or B red blood cells.
DFPP was performed using KM-8800 in a Kuraray plas-
mapheresis system incorporating a Plasmacure PS-06 and an
Evaflux 4A as the plasma fractionator (Kuraray Medical,
Tokyo, Japan). The exchange volume was set at 50 mL/kg
with normal saline 300e500 mL as the replacement fluid.
Intravenous immunoglobulin was not included in the
desensitization protocol but was employed to treat
antibody-mediated rejection, as defined by positive C4d-
staining in more than 50% of peritubular capillaries. Coag-
ulation profiles and albumin levels were regularly checked
during the pretransplant desensitization period. Frozen
plasma was only given for coagulopathy, and albumin for
hypoalbuminemia (<30 g/L).
Immunosuppressive therapy
Before transplantation, the patients receiving ABOi renal
allografts (Incompatible group) received a 7-day pre-
conditioning immunosuppressive therapy including tacroli-
mus,mycophenolatemofetil (MMF) andmethylprednisolone.
The initial dose of tacrolimuswas 0.2mg/day and that ofMMF
1e2 g/day. The target trough level for tacrolimus was
8e12mg/L, and thewhite blood cell countswerekept atmore
than 4  109/L by adjusting the dose of tacrolimus and MMF.
The daily dose of methylprednisolone was 40 mg/day.
Every renal transplant recipient, regardless of whether
or not they were ABO-incompatible, received bolus intra-
venous methylprednisolone (10 mg/kg) before vascular
reperfusion and a tacrolimus-based immunosuppressive
B cells and immunoglobulin in ABOi transplants 355therapy after transplantation. The target trough levels for
tacrolimus were around 8e12 mg/L at 1 month and 5e8 mg/
L at 12 months. The white blood cell counts were controlled
between 4  109/L and 6  109/L by adjusting the dose of
MMF. The doses of prednisolone were 20e30 mg by Day 8,
and 2.5e5 mg/day at 12 months and thereafter without
discontinuation. All patients, regardless of their cytome-
galovirus IgG status, received oral valgancyclovir prophy-
laxis for 3 months.
Measurements and statistics
After renal transplantation, the renal transplant patients of
both the Incompatible and Compatible groups received regu-
lar follow-up of renal function, complete blood cell count,
differential white blood cell count, tacrolimus trough level,
electrolytes and lymphocyte surface markers. The relative
number (percentage)ofCD19þBcells amongthe lymphocytes
was determined by flow cytometric analysis, and the absolute
B cell count was calculated from the white blood cell count,
differential lymphocyte ratio, and B cell percentage. For the
Incompatible group, the post-transplant immunoglobulin
levels were determined by protein electrophoresis and com-
pared to those beforeDFPP instead of those of theCompatible
group, as immunoglobulin levels had a significant inter-
individual variation. Continuous values reported are arith-
meticmean standard deviation. Unpaired two-tailed t tests
and Fisher’s exact tests were used for normally distributed
continuous variables and categorical variables, respectively.
A p value of 0.05 was set as the level of significance.
Results
From 2006 to 2010, 20 patients who underwent ABOi renal
transplantations received our desensitization protocol of
rituximab and DFPP. All the renal transplants are func-
tioning at present except for one transplant failure at eight
months because of BK virus nephropathy. No significant
infectious complications were noted in any of the patients.
Of the 20 cases, one had acute cellular rejection, andTable 1 Demographics of patients who underwent ABOi renal
renal transplantations (Compatible group).
Characteristics Incompatible group (n Z
Age at transplantation (y) 45.4  15.0
Sex (male:female) 6:13
Donor age (y) 42.9 2.12.9
Live donor (%) 19/19 (100%)
HLA mismatches 2.4  1.8
Blood type A incompatibility 10/19 (52.6%)
Blood type B incompatibility 9/19 (47.4%)
12-month creatinine (mg/L) 12.2  3.4
2-y cellular rejection (%) 1/19 (5.3%)
2-y graft loss (%) 1/19 (5.3%)
Follow-up [mo] (range) 38.1  20.9 (7e70)
A two-tailed Fisher’s exact test was used for categorical variables; tw
HLA Z human leukocyte antigens; NS Z not significant.another experienced antibody-mediated rejection; the
overall rejection rate was 10% (2/20). The 3-year graft and
patient survival rates were 94.7% and 100%, respectively.
However, for statistical analysis of B cells, the patient with
antibody-mediated rejection, which warranted another
course of desensitization therapy including rituximab,
DFPP, and intravenous immunoglobulin at 1 month, was
excluded from the Incompatible group. The average follow-
up duration of the remaining 19 cases was 38.1  20.9
months (range, 7e70 months).
The number of B cells of the Incompatible group was
compared to the Compatible group which included 18 ABO-
compatible renal transplant patients operated on during
the same time period. Ten patients of the Incompatible
group were blood type A incompatible, and the other nine
were type B incompatible. None of the Incompatible group
was incompatible to type A and B at the same time. The
average age at transplantation was comparable between
the Incompatible (45.4  15.0 years) and Compatible
(44.8  12.4 years) groups. The Incompatible group inclu-
ded more female patients (68.4%, 13/19) than the Com-
patible group (50%, 9/18); however, the difference was not
significant. The patient demographics and outcomes are
summarized in Table 1.
Half (50%, 9/18) of the patients in the Compatible group
received renal transplants from deceased donors. However,
none of the Incompatible group received renal transplants
from deceased donors as ABOi renal transplantations could
only be performed with scheduled preconditioning treat-
ment and live donor operations. The average donor age of
the Incompatible group (42.9  12.9 years) was higher than
that of the Compatible group (37.3  10.5 years), although
the difference did not reach statistical significance. The
mismatches in human leukocyte antigens were comparable
between the two groups, as were the serum creatinine
levels. One and four patients of the Incompatible (5.3%, 1/
19) and Compatible (22.2%, 4/18) groups, respectively, had
acute cellular rejection episodes during the 2-year study
period. All of the patients who experienced cellular
rejection episodes were successfully treated with methyl-
prednisolone pulse therapy; however, one patient in thetransplantations (Incompatible group) and ABO-compatible
19) Compatible group (n Z 18) p
44.8  12.4 0.907
9:9 0.420
37.3  10.5 0.156
9/18 (50%) 0.006
3.0  1.1 0.266
0 d
0 d
12.8  5.1 0.714
4/18 (22.2%) 0.134
1/18 (5.5%) 0.933
29.2  14.8 (7e51) 0.142
o-tailed unpaired t test was used for continuous variables.
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Figure 1 Flow cytometric analysis of (A) percentages and (B)
absolute counts of B cells in the peripheral blood of the Com-
patible and Incompatible groups. Absolute B cell counts were
calculated as follows: B cell count Z white blood cell
count  lymphocyte percentage  B cell percentage. The
differences in B cell percentages and absolute counts were
compared between the Compatible and Incompatible groups.
*p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2 Total IgG and IgM levels of the Incompatible group.
The post-transplant levels of IgG and IgM were compared to
those before desensitization. *p < 0.05; **p < 0.01;
***p < 0.001.
356 M.-K. Tsai et al.Compatible group subsequently experienced refractory
rejection and graft failure. The 2-year graft failure rates
were not significantly different between the two groups.
To demonstrate the sole effect of rituximab and DFPP,
the B cell percentage and absolute count of the Incom-
patible group were compared to the Compatible group, who
also received tacrolimus and MMF for immunosuppression,
because MMF may have suppressed B cell proliferation. For
the first 3 months after desensitization therapy, B cells
were completely undetectable in the Incompatible group
and were significantly lower than those of the Compatible
group in terms of percentage (p < 0.001) and absolute
count (p < 0.01). The average B cell percentages of the
Compatible group were 13.6  6.6%, 9.6  5.3% and
8.3  4.1% at post-transplant Month 1 to Month 3, respec-
tively, and the average counts were 316.1  238.7  106/L,
203.6  217.6  106/L and 182.5  186.2  106/L,
respectively. The average B cell count in the Incompatible
group increased gradually from zero to 13.1  18.2  106/L
at 6 months and 104.3  70.3  106/L at 12 months.
Interestingly, in the Compatible group, the average B
cell count decreased even further to 141.4  147.5  106/L
at 6 months, and then increased gradually to
184.4  128.8  106/L at 12 months. The average B cell
count of the Incompatible group was significantly lower
than that of the Compatible group post-transplant from
Month 1 to Month 11. The B cell percentages and absolute
counts of the Compatible and Incompatible groups are
summarized in Fig. 1.
With regards to immunoglobulin levels, we measured
total IgM, IgG and IgG1-4 subclasses and compared the
levels after transplantation to those before desensitization
in the Incompatible group. The average IgG and IgM levels
before desensitization were 13.69  3.657 and
0.939  0.374 g/L, respectively, and the average IgG and
IgM levels after transplantation were significantly lower
than those before desensitization during the 24-month
follow-up period. However, both IgG and IgM levels
increased from the lowest levels at 1 month to the highest
at 12 months. The average levels of IgG were
9.772  1.990 g/L at 6 months, 10.57  2.811 g/L at 12
months and 9.908  2.743 g/L at 24 months. The average
levels of IgM were 558  335 mg/L at 6 months,
660  403 mg/L at 12 months and 543  320 mg/L at 24
months. During the 24-month follow-up period, neither the
IgG nor IgM levels returned to the levels before desensiti-
zation. The total IgG and IgM levels of the Incompatible
group are shown in Fig. 2.
IgG subclasses were further measured to identify the
differential effect of rituximab. The IgG1e4 subclass levels
after desensitization were almost always significantly lower
than those before desensitization throughout the 24 months
of follow-up except for IgG3. The average IgG3 level after
transplantation was significantly lower than that before
desensitization only for the first 3 months. The levels of
IgG3 then rose progressively during the follow-up; the
average levels of IgG3 were 674  325 mg/L before
desensitization, 487  319 mg/L at 6 months,
637  387 mg/L at 12 months and 681  551 mg/L at 24
months. The desensitization therapy seemed to be less
effective in suppressing the levels of IgG3. The IgG subclass
levels of the Incompatible group are shown in Fig. 3Discussion
Rituximab has been shown to deplete B cells in renal
transplant recipients. Genberg et al reported that a single
dose of rituximab therapy could maintain B cell counts
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Figure 3 IgG subclass levels of the Incompatible group: (A)
IgG1 and IgG2, (B) IgG3 and IgG4. The post-transplant levels
were compared to those before desensitization. *p < 0.05;
**p < 0.01; ***p < 0.001.
B cells and immunoglobulin in ABOi transplants 357below 5  106 cells/L in most adult renal transplant
patients for more than 15 months.7 However, the effect of
rituximab in depleting B cells can be strengthened by
concomitant use of immunosuppressive agents such as
tacrolimus or MMF. In this study, we found that the
depleting effect of rituximab could be maintained for about
12 months in ABOi renal transplant patients. Interestingly,
there was also a noticeable trend toward a reduction in the
number of B cell in the first 6 months after transplantation
in the Compatible group (316.  238.7  106 cells/L at 1
month and 141.4  147.5  106 cells/L at 6 months). This
suggests that maintenance immunosuppressive agents such
as tacrolimus and MMF play a role in the suppression of B
cell recovery from depletion. In addition, maintenance
immunosuppressive agents may help to prolong the dura-
tion of B cell depletion after rituximab therapy for ABOi
renal transplantation patients.
The effect of B cell depletion on immunoglobulin pro-
duction was clearly seen when plasmapheresis was per-
formed without intravenous immunoglobulin. Valli et al
demonstrated that ABO immunoadsorption resulted in
median reductions of total IgM and IgG by 34% and 18%,
respectively.12 However, the IgG levels could be restored by
intravenous immunoglobulin in the short term. Although
long-term measurements of immunoglobulin levels have
been reported to be generally lower than those
before desensitization, conclusive data on long-termimmunoglobulin levels after rituximab therapy are lack-
ing. In this study, a preconditioning regimen including DFPP
and rituximab without intravenous immunoglobulin was
employed. After plasmapheresis, the immunoglobulin lev-
els dropped significantly, and the increase in immunoglo-
bulin levels could be interpreted as new production. Data
of the post-transplant immunoglobulin in the two groups
were analyzed (data not shown), but the results did not
reach statistical significance, even though DFPP was per-
formed in the Incompatible group. With paired comparison,
we were able to demonstrate that rituximab had a sus-
tained suppressive effect on antibody production of total
IgG and IgM levels in the ABOi renal transplant recipients.
Among the IgG subclasses, IgG3 was found to recover
relatively soon and seemed to be resistant to the effects of
rituximab. The IgG3 level in the ABOi patients recovered
quickly (within 3 months) from the effects of DFPP, sug-
gesting that IgG3-producing B cells were resistant to rit-
uximab. This phenomenon is compatible with the findings
of Uchida et al in their murine model in which anti-CD20
antibodies depleted B cells through Fc receptor-dependent
pathways with a hierarchy of IgG2a/c > IgG1/2b > IgG3.13
FcgR expression profiles of B cells have been found to
affect the dynamics of B cell subset depletion through
targeting CD20.14,15 Fortunately, IgG3 is rarely induced in
situations of ABO incompatibility, and the predominant IgG
subclass has been shown to be IgG2 rather than IgG3.16,17
The sole effect of rituximab on B cells could hardly be
revealed without a proper control group. Patients who
needed rituximab therapy received concomitant immuno-
suppressive therapy; the immunological deviations from
baseline levels were actually effects of therapeutic com-
binations.18,19 Accordingly, we employed data from ABO-
compatible transplant patients who did not received rit-
uximab but the same immunosuppressive regimen as the
control in this study. However, this is not a two-arm
randomized control study; it is manifestly impossible to
randomize patients of ABOi renal transplantation to receive
no rituximab therapy. Besides, DFPP was totally unneces-
sary for compatible and crossmatch-negative renal trans-
plant patients. Considering the complicated regulatory
mechanisms of immunoglobulin production and inter-
individual variations, we chose to compare the immuno-
globulin levels after transplantation to those before
desensitization in one study group.20,21
The overall rejection rate of the ABOi renal transplant
patients (2/20, 10%) seemed to be lower than that of the
compatible patients (4/18, 22.2%). Rituximab has been
demonstrated to inactivate T cells resulting in a significant
decrease in cytokine production and proliferative capacity
in lymphoma patients.22 However, Clatworthy et al repor-
ted an increased rejection rate in patients receiving tra-
ditional immunosuppressive therapy with rituximab
induction.23 In contrast, increased infectious complica-
tions, especially viral infections, were found in a small
group of ABOi renal transplant patients receiving rituximab
induction with valgancyclovir prophylaxis, but only in those
at high-risk (Dþ, R).24 In-depth mechanistic research and
large-scale randomized controlled clinical studies are
warranted to examine the advantages and disadvantages of
rituximab therapy for renal transplantation.
358 M.-K. Tsai et al.In conclusion, maintenance immunosuppression with
tacrolimus and MMF may play a role in the suppression of B
cell count in ABOi renal transplant patients treated with
rituximab and DFPP. The total IgG and IgM levels were
steadily suppressed at 2 years; however IgG3 seemed rel-
atively resistant to the effects of rituximab.
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